HomeNewsBusinessCompaniesWhy potential vaccine-related legal liabilities worry Covid-19 vaccine makers

Why potential vaccine-related legal liabilities worry Covid-19 vaccine makers

As part of their purchase pacts, some countries have agreed to indemnify vaccine makers against claims following any adverse effects. India has not agreed to this so far. Executives of vaccine makers are also worried about the high cost of product liability covers they will have to buy given the limited data on adverse effects at this stage

January 19, 2021 / 20:01 IST
Story continues below Advertisement
Representative Image
Representative Image

With the government not extending indemnity to Covid-19 vaccine makers, there has been some disquiet among companies about the potential litigation that may arise due to unforeseen complications from Covid-19 vaccines.

It isn’t just the potential litigation of vaccine-linked serious adverse events; executives of vaccine makers are also worried about the high cost of product liability covers they have to buy given the limited data on adverse effects at this stage.

Story continues below Advertisement

Serum Institute of India (SII) and Bharat Biotech haven’t responded to questions sent by Moneycontrol on the government not extending indemnity.

Adar Poonawalla, CEO of SII, which is manufacturing and distributing the AstraZeneca-Oxford University Covid-19 vaccine in India, had earlier asked the government to indemnify vaccine manufacturers. “We need to have the government indemnify manufacturers, especially vaccine manufacturers, against all lawsuits. In fact, COVAX and other countries have already started talking about that,” Poonawalla said at the Carnegie India’s Global Technology Summit in December. (COVAX is a global collaboration for speedy development, production and equitable distribution of new vaccines worldwide.)

COVID-19 Vaccine
Frequently Asked Questions

View more

How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.
View more
+ Show